Erica Spatz, MD, MHS
Associate Professor of Cardiology and Associate Professor of Epidemiology (Chronic Diseases)Cards
About
Research
Publications
2026
Efficacy of glucagon-like-peptide-1 agonists for weight loss in adults with CHD.
Varghese P, Elder R, Vinocur J, Spatz E, Shabanova V, McCollum S, Harper M, Pastor T. Efficacy of glucagon-like-peptide-1 agonists for weight loss in adults with CHD. Cardiology In The Young 2026, 1-7. PMID: 42290594, DOI: 10.1017/s1047951126113109.Peer-Reviewed Original ResearchCongenital heart diseaseGlucagon-like-peptide-1Glucagon-like-peptide-1 agonistsMonths of treatmentRetrospective cohort studyACHD patientsWeight lossCongenital heart disease complexitySide effectsHeart diseasePeriod of follow-upSide effect profileYale-New Haven HospitalManagement of obesityACHD groupACHD populationEffect profileNew Haven HospitalFollow-upAcid refluxPrimary outcomeGlycaemic controlSecondary outcomesAgonistsACHDCardiovascular outcomes in individuals with ovarian cancer: A retrospective cohort study
AlAshqar A, Clark M, Gross C, Spatz E, Xu X. Cardiovascular outcomes in individuals with ovarian cancer: A retrospective cohort study. Gynecologic Oncology 2026, 211: 17-22. PMID: 42287764, DOI: 10.1016/j.ygyno.2026.06.008.Peer-Reviewed Original ResearchMajor adverse cardiovascular eventsNon-cancer controlsOvarian cancer patientsRetrospective cohort studyCardiovascular diseaseCohort studyOvarian cancerMajor adverse cardiovascular events riskCancer patientsSub-distribution hazard modelCardiovascular disease riskRisk of cardiovascular diseaseBilateral oophorectomyNon-cancer patientsCardiovascular risk factorsFine-Gray sub-distribution hazard modelOptum Labs Data WarehouseIncident major adverse cardiovascular eventsAcute myocardial infarctionClaims dataOutcome measuresAdverse cardiovascular eventsHazards modelRisk factorsTransient ischemic attackIdentifying social determinants of health subgroups and their associations with health outcomes in a prospective US adult COVID-19 cohort: an analysis of the INSPIRE registry
Burrola-Mendez Y, Lin E, Parrish C, Hsu C, Hill M, Gottlieb M, Rising K, Wisk L, Gentile N, Geyer R, Weinstein R, Santangelo M, Gatling K, Dyal J, Elmore J, Rodriguez R, Watts P, Chen J, Diao Z, Spatz E, Chan K, Stephens K, O’Laughlin K, Group T, Weinstein R, Santangelo M, Koo K, Derden A, Gottlieb M, Gatling K, Ahmed Z, Hassaballa M, Kaadan A, Venkatesh A, Spatz E, Kinsman J, Malicki C, Lin Z, Li S, Yu H, Mannan I, Yang Z, Liu M, Chen J, Chen P, Venkatesh A, Spatz E, Ulrich A, Kinsman J, Malicki C, Dorney J, Pierce S, Puente X, Salah W, Diao Z, Nichol G, Stephens K, Anderson J, Schiffgens M, Adams K, Stober T, Maat Z, O’Laughlin K, Gentile N, Geyer R, Willis M, Zhang Z, Chang G, Lyon V, Klabbers R, Ruiz L, Malone K, Rising K, Kean E, Chang A, Renzi N, Watts P, Kelly M, Schaeffer K, Grau D, Cheng D, Shutty C, Charlton A, Shughart L, Shughart H, Amadio G, Miao J, Elmore J, Wisk L, L’Hommedieu M, Chandler C, Eguchi M, Roldan K, Moreno R, Rodriguez R, Wang R, Montoy J, Kemball R, Chan V, Chavez C, Wong A, Arreguin M, Hill M, Site R, Kane A, Nikonowicz P, Sapp S, Idris A, McDonald S, Gallegos D, Martin K, Saydah S, Plumb I, Hall A, Briggs-Hagen M. Identifying social determinants of health subgroups and their associations with health outcomes in a prospective US adult COVID-19 cohort: an analysis of the INSPIRE registry. BMJ Open 2026, 16: e105749. PMID: 42276798, PMCID: PMC13295834, DOI: 10.1136/bmjopen-2025-105749.Peer-Reviewed Original ResearchConceptsSocial determinantsLatent class analysisHealth outcomesMental healthLower pain interferenceUS academic medical centreUS prospective cohortsCognitive functionMental health domainsReference groupFollow-upAcademic medical centreCross-sectional analysisProspective cohort studyCOVID-19-related health outcomesLongitudinal data collectionSDOH factorsHealth subgroupsPain interferencePhysical functionSARS-CoV-2 testingEligible participantsNon-HispanicPersistent disparitiesHealth domainsHealthcare utilization and health expenditures among U.S. adults by cancer and atherosclerotic cardiovascular disease status.
Mansur Z, Mszar R, Cueva G, Barac A, Spatz E, Desai N, Rana J, Nasir K. Healthcare utilization and health expenditures among U.S. adults by cancer and atherosclerotic cardiovascular disease status. Journal Of Clinical Oncology 2026, 44: e23191-e23191. DOI: 10.1200/jco.2026.44.16_suppl.e23191.Peer-Reviewed Original ResearchPopulation of cancer survivorsOffice-based visitsHealthcare utilizationAtherosclerotic cardiovascular diseaseHealth expenditureCancer survivorsSelf-reported cancerMedical Expenditure Panel SurveyHealthcare utilization outcomesPrescription medication useConfidence intervalsSources of careEmergency department visitsCardiometabolic risk factorsCardiovascular disease statusMultivariate logistic regression modelLogistic regression modelsNoncancer comorbiditiesUtilization outcomesRisk of atherosclerotic cardiovascular diseaseDepartment visitsSociodemographic characteristicsU.S. adultsPrescription medicationsHealthcare expendituresSingle-Pill Combination Therapy for Hypertension Persistent Underuse in the United States, 2015-2025
Choi K, Kim C, Spatz E, Krumholz H, Lu Y. Single-Pill Combination Therapy for Hypertension Persistent Underuse in the United States, 2015-2025. Journal Of The American College Of Cardiology 2026 PMID: 42089854, DOI: 10.1016/j.jacc.2026.03.088.Peer-Reviewed Original ResearchPutting the 2026 Dyslipidemia Guideline Into Action in Primary Care Implementation Challenges and Opportunities
Sterling M, Spatz E. Putting the 2026 Dyslipidemia Guideline Into Action in Primary Care Implementation Challenges and Opportunities. Journal Of The American College Of Cardiology 2026, 87: 2584-2586. PMID: 42153693, DOI: 10.1016/j.jacc.2026.03.058.Peer-Reviewed Original ResearchLow-Level Airborne Particulate Matter and Risk of Hypertension Hospitalization in Older U.S. Adults
Zhang Y, Zhang S, Wang Y, Spatz E, Krumholz H, Lu Y, Chen K. Low-Level Airborne Particulate Matter and Risk of Hypertension Hospitalization in Older U.S. Adults. Journal Of The American College Of Cardiology 2026, 87: 2826-2842. PMID: 41984014, DOI: 10.1016/j.jacc.2026.02.5112.Peer-Reviewed Original ResearchConceptsAnnual PM2.5 concentrationsEffects of PM2.5Quasi-Poisson regression modelParticulate matterExposure to PM2.5 concentrationsLong-term exposure to fine particulate matterExposure to fine particulate matterFine particulate matterAir quality standardsAirborne particulate matterAnnual standardRegulatory thresholdsQuality standardsContiguous United StatesHypertension hospitalizationsSuburban areasSocioeconomically deprived neighborhoodsOlder U.S. adultsRegulatory standardsRegression modelsConcentrationDeprived neighbourhoodsEffect modificationGreater vulnerabilityOlder adultsCardiovascular digital twins using a Windkessel physics informed neural network
Osman D, Sel K, Spatz E, Jafari R. Cardiovascular digital twins using a Windkessel physics informed neural network. Npj Digital Medicine 2026, 9: 443. PMID: 41965786, PMCID: PMC13254049, DOI: 10.1038/s41746-026-02610-9.Peer-Reviewed Original ResearchBending the Curve in Hypertension Management It Is Time for a Fundamentally Different Approach
Spatz E, Jones D. Bending the Curve in Hypertension Management It Is Time for a Fundamentally Different Approach. Journal Of The American College Of Cardiology 2026, 87: 2352-2354. PMID: 41949513, DOI: 10.1016/j.jacc.2026.02.5082.Peer-Reviewed Original ResearchThe AHA/ACC Guideline for Pulmonary Embolism A New Era in Diagnosis, Risk Assessment, and Management
Bikdeli B, Watson N, Malejczyk J, Bonaca M, Bittl J, Spatz E, Krumholz H. The AHA/ACC Guideline for Pulmonary Embolism A New Era in Diagnosis, Risk Assessment, and Management. Journal Of The American College Of Cardiology 2026, 87: 1530-1534. PMID: 41949219, DOI: 10.1016/j.jacc.2025.12.089.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Erica Spatz, MD, MHS, is a general cardiologist who treats a variety of conditions that relate to the heart and circulatory system. In addition to emphasizing prevention to her patients, she is an active researcher who investigates ways to prevent heart attacks and strokes, so that more people can live long and healthy lives.
“The field of prevention is exciting. We are rapidly developing new ways of estimating people’s risk of future heart disease, and we have new medications and tools to reduce that risk,” says Dr. Spatz, who is especially interested in applying “precision medicine” to prevention. This is making conversations with patients in her practice more specific and less generic. “I am thinking, ‘What are the patient’s risk factors? What's unique about their biology, their genetics, and their biography? What are the aspects of their lives that may be contributing to cardiovascular risk or, on the contrary, promoting cardiovascular health? What might be the best strategies for reducing risk and improving their health outcomes?’ The onus is on us as clinicians, physicians, nurses, and pharmacists, to really understand the person before us.”
We need to be working at multiple levels to reduce heart disease, Spatz says. “We need strong policies and coordinated community efforts to promote healthier lifestyles and overall well-being. There is so much we can be doing to make ‘healthy’ the easy choice for our population. At the individual level, there is an opportunity to better capture the personalized biological factors, experiences, and behaviors that inform cardiovascular risk—through digital technology and surveys.”
Lifestyle changes are often considered the bedrock of preventing heart disease, and while this can be difficult for some people—especially if they are overwhelmed with other life challenges—small achievable goals go a long way, Dr. Spatz says. “I try to think about this from a lifelong perspective. Cardiovascular disease prevention is hard work and people can't be perfect all the time, so I try to find specific things people can work on as well as opportunities when this makes sense in a person's life. If I can help them to define a healthier path, then I think the ripple effects can be massive.”
In addition to caring for patients, Dr. Spatz serves as a clinical investigator for the Center for Outcomes Research & Evaluation (CORE), an organization at Yale School of Medicine that focuses on health care quality, where she researches individualized approaches to preventing and managing cardiovascular disease, health disparities across the health care system, and ways to engage patients as partners in their care. She also is a cofounder of Project Access-New Haven—a network of physicians, hospitals, and community organizations partnering to provide donated specialty care to underserved patients in New Haven.
Clinical Specialties
Fact Sheets
Heart Attack (Myocardial Infarction)
Learn More on Yale MedicineFamilial hypercholesterolemia
Learn More on Yale MedicineHypercholesterolemia (High Cholesterol)
Learn More on Yale MedicineCOVID-19
Learn More on Yale Medicine
Yale Medicine News
News & Links
Media
- Dr. Erica Spatz is developing a more personalized, precision-based approach to diagnosing and treating women who display different kinds of evidence of heart attacks.
News
- July 05, 2026Source: The New York Times (with Erica Spatz, MD)
The wearable data your doctor actually wants
- May 04, 2026Source: Yahoo Australia (with Erica Spatz, MD)
Sex Matters: The Heart Disease Risk Women Can't Afford To Miss
- March 16, 2026Source: Yale Medicine
Should You Take a Statin for Your High Cholesterol?
- December 29, 2025Source: Yahoo UK - Yahoo Movies UK
75% of US adults may meet criteria for obesity under new definition, study finds
Get In Touch
Contacts
Cardiovascular Medicine
789 Howard Avenue, PO Box 208017
New Haven, CT 06520-8017
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.